Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster I
Friday, November 6, 2020
9:00 AM – 11:00 AM ET
Poster session.
Presentations:
9:00 AM – 11:00 AM ET
Effectiveness and Safety of Apremilast in Biologic-Naive versus Biologic-Experienced Patients with Psoriatic Arthritis in Real-World Clinical Practice Settings in Germany: Interim Analysis of an Ongoing, Multicenter, Prospective, Non-interventional Study Jurgen Wollenhaupt – Rheumatologie im Struenseehaus
9:00 AM – 11:00 AM ET
Safety Profiles of Ixekizumab versus Adalimumab: 52-Week Results from a Head-to-Head Comparison in Patients with Active Psoriatic Arthritis Philip J. Mease, MD – Seattle Rheumatology Associates
9:00 AM – 11:00 AM ET
In Two Phase-3 Trials, Guselkumab Reduced Fatigue over 52 Weeks in Patients with Psoriatic Arthritis and Demonstrated Independent Treatment Effects on Fatigue After Adjustment for Clinical Response (ACR20) Proton Rahman, MD – Memorial University
9:00 AM – 11:00 AM ET
Biologics History and Sex Are Linked to Golimumab Discontinuation in Axial Spondyloarthritis: A Sub-Analysis of the Post-Registration GO-Practice Study Rene-Marc Flipo – Lille University Hospital
9:00 AM – 11:00 AM ET
Pooled Safety Results from Two Phase-3 Trials of Guselkumab in Patients with Psoriatic Arthritis Through 1 Year Christopher Ritchlin, MD, MPH – University of Rochester Medical Center
9:00 AM – 11:00 AM ET
The Impact of Age and Time Since Diagnosis on Response to Treatment with Secukinumab in Pooled Week 52 Data from 4 Phase 3 Studies in Patients with Ankylosing Spondylitis Atul Deodhar, MD – Oregon Health & Science University
9:00 AM – 11:00 AM ET
Ustekinumab-Treated Patients with Psoriatic Arthritis in a Real-world Study: Similar Clinical Responses and Treatment Persistence over One Year in Elderly and Younger Patients Laure Gossec, MD, PhD – Sorbonne Universite and Pitie-Salpetriere Hospital
9:00 AM – 11:00 AM ET
Efficacy and Safety of Ixekizumab versus Adalimumab with and Without Concomitant Conventional Synthetic Disease-Modifying Antirheumatic Drugs (DMARD) in Biologic DMARD-Naïve Patients with Psoriatic Arthritis: 52-Week Results Josef S. Smolen, MD – Medical University of Vienna
9:00 AM – 11:00 AM ET
Achievement of Sustained Remission and Low Disease Activity with Secukinumab Improves Quality of Life and Physical Function in Patients with Psoriatic Arthritis: Results from a Randomized Phase 3 Study Laura C. Coates, PhD, MBChB – University of Oxford
9:00 AM – 11:00 AM ET
Suppressing Inflammation Rather Than Lowering the Disease Activity Score Should Be Targeted During TNF Inhibitor Treatment to Slow Radiographic Changes in Patients with Ankylosing Spondylitis Bon San Koo, MD – Inje University Seoul Paik Hospital
9:00 AM – 11:00 AM ET
Does Smoking Affect Secukinumab Treatment Outcomes and Safety in Patients with Ankylosing Spondylitis? – Real World Data from German Observational Study Uta Kiltz, MD – Rheumazentrum Ruhrgebiet, Ruhr-University Bochum
9:00 AM – 11:00 AM ET
Clinical Characteristics of Psoriatic Arthritis Patients with Physician-Identified Spondylitis, According to HLA-B27 Status: An Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry Philip J. Mease, MD – Seattle Rheumatology Associates
9:00 AM – 11:00 AM ET
Does Smoking Affect Secukinumab Treatment Outcomes and Safety in Patients with Psoriatic Arthritis? – Real World Data from German Observational Study Uta Kiltz, MD – Rheumazentrum Ruhrgebiet, Ruhr-University Bochum
9:00 AM – 11:00 AM ET
Response to Treatment with Ixekizumab in Patients with Active Non-Radiographic Axial Spondyloarthritis Based on HLA-B27 Status and Disease Duration Marina Magrey, MD – Case Western Reserve University School of Medicine at MetroHealth Medical Center
9:00 AM – 11:00 AM ET
Patients with Psoriatic Arthritis Treated with Guselkumab Achieved Psoriasis-Related Symptom-Free State and Had No Skin Condition Impact on Their Health Related Quality of Life Jan Dutz, MD – University of British Columbia
9:00 AM – 11:00 AM ET
Efficacy of Ixekizumab on Disease Activity and Quality of Life in Patients with Active Nonradiographic Axial Spondyloarthritis and Objective Signs of Inflammation, Stratified by Baseline CRP/Sacroiliac Joint MRI Status Walter P. Maksymowych, MD, FRCPC – University of Alberta
9:00 AM – 11:00 AM ET
Subcutaneous Secukinumab 150 Mg Provides Sustained Relief in Total and Nocturnal Back Pain, Morning Stiffness, Fatigue, and Low Disease Activity in Patients with Active Ankylosing Spondylitis: End-of-study (5-year) Data from the MEASURE 2 Trial Helena Marzo-Ortega, PhD – Leeds Teaching Hospitals Trust
9:00 AM – 11:00 AM ET
Experience with Apremilast in Treatment of Psoriatic Arthritis in US Clinical Practice; Assessments from Trio Health and the American Rheumatology Network (ARN) Colin Edgerton, MD – Articularis Healthcare
9:00 AM – 11:00 AM ET
Symptoms of Peripheral Arthritis Are Significantly Improved in Patients with Ankylosing Spondylitis Treated with Secukinumab Philip J. Mease, MD – Seattle Rheumatology Associates
9:00 AM – 11:00 AM ET
Guselkumab Induces Sustained Reduction in Acute Phase Proteins and Th17 Effector Cytokines in Active Psoriatic Arthritis in Two Phase-3 Clinical Trials (DISCOVER-1 and DISCOVER-2) Stefan Siebert, MD, PhD – University of Glasgow
9:00 AM – 11:00 AM ET
Comparable Impact and Burden of Disease of Psoriatic Arthritis Patients with Limited Joint Involvement vs. Those with More Extensive Joint Involvement: Interim Results from a Prospective, Multicenter, Real-World Study in Patients Treated with Apremilast Tim L. Jansen, MD PhD – Viecuri MC
9:00 AM – 11:00 AM ET
Effect of Upadacitinib on Reducing Pain in Patients with Active Ankylosing Spondylitis and Inadequate Response to Nonsteroidal Anti-inflammatory Drugs Atul Deodhar, MD – Oregon Health & Science University
9:00 AM – 11:00 AM ET
Guselkumab-Treated Patients Achieved Clinically Meaningful Improvement in Systemic Symptoms as Measured with PROMIS Instrument: Results from Phase-3 Psoriatic Arthritis Trial DISCOVER 1 Ana-Maria Orbai, MD, MHS – Johns Hopkins University School of Medicine, Division of Rheumatology
9:00 AM – 11:00 AM ET
Identifying Inadequate Response Among Ankylosing Spondylitis Patients Prescribed Biologics in a Real-world Commercially Insured Adult Population in the United States Michael Grabner, PhD – HealthCore, Inc.
9:00 AM – 11:00 AM ET
Tumor Necrosis Factor-α Receptor 2 Polymorphisms and Response to TNF Inhibitor Therapy in Patients with Psoriatic Arthritis Sarah Rasheed, MD – cleveland clinic
9:00 AM – 11:00 AM ET
Medical Cannabis in Ankylosing Spondylitis Following Recreational Legalization: A Prospective Cross-sectional Study Mary-Ann Fitzcharles, MD – McGill University
9:00 AM – 11:00 AM ET
Neo-epitopes of Type I Collagen Can Be Utilized as Translational Biomarkers for Skin and Joint Turnover in Patients with Psoriasis and Psoriatic Arthritis Solveig S. Groen, BSc, MSc – University of Copenhagen
9:00 AM – 11:00 AM ET
Efficacy of Disease Modifying Anti-Rheumatic Drugs for Enthesitis in a Prospective Longitudinal Psoriatic Arthritis Cohort Ashish Mathew, MD – University Health Network
9:00 AM – 11:00 AM ET
Higher Intake of Carbohydrates and Free Sugar Are Associated with Higher Disease Activity in Patients with Axial Spondyloarthritis Valeria Rios Rodriguez, MD – Charité Universitätsmedizin Berlin
9:00 AM – 11:00 AM ET
Evaluation of Sex Differences in the Efficacy and Safety of Tofacitinib in Patients with Active Psoriatic Arthritis: A Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials Lihi Eder, MD, PhD – University of Toronto
9:00 AM – 11:00 AM ET
Itch as the Major Mediator of the Effect of Tofacitinib on Health-Related Quality of Life in Psoriatic Arthritis: A Mediation Analysis Joseph F. Merola, MD, MSc – Brigham and Women's Hospital
9:00 AM – 11:00 AM ET
Achievement of RAPID3 and cDAPSA Treatment Targets Is Associated with Control of Articular and Extra-Articular Manifestations of Active Psoriatic Arthritis in DMARD-Naive Patients Treated with Apremilast Philip J. Mease, MD – Seattle Rheumatology Associates
9:00 AM – 11:00 AM ET
Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3 Year Results from a Phase 3 Study Arnaud Constantin, MD, PhD – Toulouse University Hospital
9:00 AM – 11:00 AM ET
Efficacy of Tofacitinib on Dactylitis in Individual Digits in Patients with Active Psoriatic Arthritis Ana-Maria Orbai, MD, MHS – Johns Hopkins University School of Medicine, Division of Rheumatology
9:00 AM – 11:00 AM ET
Bimekizumab Improves Patient-Reported Outcomes in Psoriatic Arthritis: 48-Week Results from a Phase 2b Study and Association Between Patient-Reported Outcomes and Disease Activity Laure Gossec, MD, PhD – Sorbonne Universite and Pitie-Salpetriere Hospital
9:00 AM – 11:00 AM ET
How Do TNF-alpha-Inhibitors in Medical History Affect Patient Reported Outcomes and Retention in Ankylosing Spondylitis Patients Treated with Secukinumab in Real World? – German Observational Study Uta Kiltz, MD – Rheumazentrum Ruhrgebiet, Ruhr-University Bochum
9:00 AM – 11:00 AM ET
Collagen Turnover Markers Are Associated with Active Psoriatic Arthritis and Decrease with Guselkumab Treatment in a Phase-3 Clinical Trial Georg Schett, MD – Universitaetsklinikum Erlangen
